BioFactura, Inc. has recently expanded its lease at Riverside Tech Park in Frederick, Maryland with St. John Properties, Inc., securing an additional 12,000 square feet of space for a total of 17,520 square feet. This expansion follows the biotechnology firm’s $78 million contract from BARDA to develop their Smallpox Biodefense Therapeutic.
According to Dr. Jeffrey Hausfeld, Chairman of the Board and Chief Medical Officer at BioFactura: “The I-270 corridor is among the top five locations nationally for attracting life sciences talent and this played a significant role in our decision to move to Frederick.” He also noted that the region offers an affordable lifestyle with less congestion compared to areas closer to Washington D.C., making it ideal for their operations as a pharmaceutical manufacturer and distributor.
The new facility is set to open this fall and boasts flexible layout options including rear loading capabilities that perfectly meet BioFactura’s needs.
